Intelligent Bio Solutions reports Q2 EPS ($2.82) vs. ($4.96) last year

Reports Q2 revenue $896,774 vs. $607,494 last year. “Our second quarter figures demonstrate consistency and solid progress across our business,” said Harry Simeonidis, President and CEO of INBS. “Reader sales more than doubling shows market demand for our non-invasive fingerprint drug testing technology and significantly expands our installed base, the engine for future recurring revenue. Equally important is the 33% growth in cartridge sales, which confirms existing customers are actively using our system and reordering consumables. This is our razor-razorblade model working as designed – hardware placements create the foundation, and consumable sales deliver ongoing revenue. With strong year-over-year growth and first-half revenue exceeding $2 million, we’re building sustainable momentum as we advance our regulatory pathway toward planned U.S. market entry.”